310 related articles for article (PubMed ID: 28017793)
1. Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
Rhedin S; Galanis I; Granath F; Ternhag A; Hedlund J; Spindler C; Naucler P
Clin Microbiol Infect; 2017 Apr; 23(4):247-252. PubMed ID: 28017793
[TBL] [Abstract][Full Text] [Related]
2. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal urinary antigen testing for antimicrobial guidance in community-acquired pneumonia-A register-based cohort study.
Athlin S; Magnuson A; Spindler C; Hedlund J; Strålin K; Nauclér P
J Infect; 2022 Aug; 85(2):167-173. PubMed ID: 35618153
[TBL] [Abstract][Full Text] [Related]
4. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
[TBL] [Abstract][Full Text] [Related]
6. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic treatment strategies for community-acquired pneumonia in adults.
Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
Reeves SD; Hartmann AP; Tedder AC; Juang PA; Hofer M; Kollef MH; Micek ST; Betthauser KD
Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
[TBL] [Abstract][Full Text] [Related]
10. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
11. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
[TBL] [Abstract][Full Text] [Related]
12. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
[TBL] [Abstract][Full Text] [Related]
13. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Mortensen EM; Restrepo MI; Anzueto A; Pugh J
Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
[TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Ewig S; Hecker H; Suttorp N; Marre R; Welte T;
J Infect; 2011 Mar; 62(3):218-25. PubMed ID: 21276814
[TBL] [Abstract][Full Text] [Related]
15. Benzylpenicillin versus wide-spectrum beta-lactam antibiotics as empirical treatment of Haemophilus influenzae-associated lower respiratory tract infections in adults; a retrospective propensity score-matched study.
Thegerström J; Månsson V; Riesbeck K; Resman F
Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1761-1775. PubMed ID: 29961165
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
[TBL] [Abstract][Full Text] [Related]
18. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
[TBL] [Abstract][Full Text] [Related]
19. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]